MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages

Br J Haematol. 2013 Mar;160(6):779-84. doi: 10.1111/bjh.12175. Epub 2012 Dec 18.

Abstract

Benefit from cytotoxic therapy in myeloma may be limited by the persistence of residual tumour cells within protective niches. We have previously shown that monocytes/macrophages acquire a proinflammatory transcriptional profile in the myeloma microenvironment. Here we report constitutive activation of MAP3K8 kinase-dependent pathways that regulate the magnitude and extent of inflammatory activity of monocytes/macrophages within myeloma niches. In myeloma tumour cells, MAP3K8 acts as mitogen-induced MAP3K in mitosis and is required for TNFα-mediated ERK activation. Pharmacological MAP3K8 inhibition results in dose-dependent, tumour cell-autonomous apoptosis despite contact with primary stroma. MAP3K8 blockade may disrupt crucial macrophage-tumour cell interactions within myeloma niches.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • MAP Kinase Kinase Kinases / antagonists & inhibitors
  • MAP Kinase Kinase Kinases / metabolism*
  • Macrophages / enzymology*
  • Macrophages / pathology*
  • Monocytes / enzymology*
  • Monocytes / pathology*
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / enzymology*
  • Multiple Myeloma / pathology*
  • Neoplasm, Residual
  • Protein Kinase Inhibitors / pharmacology
  • Proto-Oncogene Proteins / antagonists & inhibitors
  • Proto-Oncogene Proteins / metabolism*
  • Tumor Cells, Cultured

Substances

  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins
  • MAP Kinase Kinase Kinases
  • MAP3K8 protein, human